Effect of Glucagon Like Peptide 1| (GLP1) Analogues on Obese Egyptians With and Without Diabetes | ||||
| The Medical Journal of Cairo University | ||||
| Article 58, Volume 87, September, September 2019, Page 3205-3208 PDF (275.05 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/mjcu.2019.65613 | ||||
 View on SCiNiTO | ||||
| Author | ||||
| KHALED A. ELBANA, M.D. | ||||
| The Department of Internal Medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt | ||||
| Abstract | ||||
| Abstract Background: The Glucagon Like Peptide 1 (GLP1) recep-tor agonists are a new class for treatment of both type 2 diabetes and obesity. Aim of Study: To evaluate efficacy of GLP1 analogues in both weight reduction and glycemic control in obese Egyptians with and without diabetes. Patients and Methods: This intervention study was con-ducted from August 2017 to August 2018. Total of 40 patients were divided into 3 groups: Obese group, obese group with diabetes & obese group with diabetes after failure to lose 10% of their initial weight after bariatric surgery. Clinical data were collected, anthropometric measures and laboratory investigation included fasting blood glucose and HbA1c in the beginning and every 3 months for a year were done. Results: This study showed statistically significant body weight and BMI reduction in all groups, there was statistically significant reduction of fasting blood glucose, and HBA1c in the 2nd & 3rd group. Conclusion: GLP1 analogues are effective in treatment of obese patients with and without diabetes. | ||||
| Keywords | ||||
| GLP1 analogues; Type 2 Diabetes; Obesity | ||||
|
Statistics Article View: 653 PDF Download: 716 |
||||
